News >

Brahmer Shares Next Steps for Immunotherapy in Metastatic NSCLC

Brandon Scalea
Published: Friday, Nov 30, 2018

Julie R. Brahmer, MD

Julie R. Brahmer, MD
Immunotherapy has been established as the standard of care for patients with metastatic non–small cell lung cancer (NSCLC), and the next steps for research are creating a more personalized approach for individual patients, said Julie R. Brahmer, MD.

Three studies—KEYNOTE-024, KEYNOTE-189, and KEYNOTE-407—were pivotal in cementing pembrolizumab’s (Keytruda) role in the metastatic setting for patients with squamous and nonsquamous NSCLC.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication